Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences : Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine

share with twitter share with LinkedIn share with facebook
share via e-mail
10/06/2017 | 11:07am CEST

Release date- 05102017 - FOSTER CITY, Calif. - Gilead Sciences, Inc.(NASDAQ: GILD) today announced detailed 48-week results from a Phase 3 study (Study 1878) evaluating the efficacy and safety of switching virologically suppressed HIV-1 infected adult patients from a multi-tablet regimen containing a boosted protease inhibitor (bPI) to a fixed-dose combination of bictegravir (50 mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF), a dual-NRTI backbone.

In the ongoing study, BIC/FTC/TAF was found to be statistically non-inferior to regimens containing bPIs and demonstrated no treatment-emergent resistance at 48 weeks. The data are being presented at IDWeek 2017 in San Diego (Session 228).

'These data demonstrate the potential of BIC/FTC/TAF to match the efficacy of a boosted protease inhibitor regimen while also offering a high barrier to resistance and fewer interactions with other drugs,' said Eric Daar, MD, Chief of the Division of HIV Medicine at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and lead author of Study 1878. 'The findings, along with data from three other Phase 3 studies in both treatment-experienced and treatment-naive patients, suggest that the investigational regimen of BIC/FTC/TAF may be appropriate for a broad range of people living with HIV.'

In Study 1878, a total of 577 virologically suppressed adults with HIV taking regimens of boosted atazanavir (ATV) or darunavir (DRV) + abacavir/lamivudine (ABC/3TC) or FTC/tenofovir disoproxil fumarate (TDF) were randomized 1:1 to continue their bPI regimen or to switch to open-label coformulated BIC/FTC/TAF once daily. At the primary endpoint of Week 48, switching to BIC/FTC/TAF was non-inferior to continuing on a bPI regimen with 1.7 percent of patients in each group having HIV-1 RNA 50 c/mL (difference: 0.0 percent, 95 percent CI: -2.5 percent to 2.5 percent, p=1.00); the proportion of patients with HIV-1 RNA

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES
10:55a GILEAD SCIENCES : - Kite's Yescarta Becomes First CAR T Therapy Approved by the ..
10/20 GILEAD SCIENCES : FDA approves new cancer treatment with Israeli pedigree
10/20 GILEAD SCIENCES : Announces Multiple Scientific Presentations Demonstrating High..
10/20 GILEAD SCIENCES : Jumps After FDA Approves Its Kite-Acquired CAR-T Drug
10/19 GILEAD SCIENCES : to Release Third Quarter 2017 Financial Results on Thursday, O..
10/19 GILEAD SCIENCES : Study Findings from Gilead Sciences Provide New Insights into ..
10/19 GILEAD SCIENCES : Patent Issued for Processes and Intermediates for Preparing an..
10/19 GILEAD SCIENCES : Patent Issued for Salts of HIV Inhibitor Compounds (USPTO 9783..
10/19 GILEAD SCIENCES : names new head of oncology therapeutics
10/19 GILEAD SCIENCES : 2nd gene therapy for blood cancer approved
More news
News from SeekingAlpha
12:37p Alpine extends research term under Kite Pharma deal
08:00a 3 THINGS, OCTOBER 23, 2017 : Gilead's Viral Juggernaut Grows, Omeros Adds Eviden..
10/22 More Wizardry For 2017 -- Magic Formula Large Cap Strategy Update, 2017 YTD
10/20 CytoDyn Dresses HIV Patients In CCR5 Halloween 'Mask'
Financials ($)
Sales 2017 25 994 M
EBIT 2017 15 921 M
Net income 2017 10 622 M
Debt 2017 13 436 M
Yield 2017 2,60%
P/E ratio 2017 10,13
P/E ratio 2018 11,93
EV / Sales 2017 4,60x
EV / Sales 2018 5,11x
Capitalization 106 B
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 85,3 $
Spread / Average Target 5,0%
EPS Revisions
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES13.41%106 054
ACTELION24.15%29 840
GENMAB13.21%12 865
EXELIXIS, INC.82.23%7 985